Lantheus Holdings Inc

LNTH

Equity

ISIN null / Valor 24784644

NASDAQ (2025-11-20)

USD 53.59+1.52%

Lantheus Holdings Inc
UMushroom community rating:

4.57 3 votes No rating yet

NegativeNeutralPositive

About company

Lantheus Holdings Inc. is a prominent player in the healthcare sector, specializing in the development, manufacture, and commercialization of innovative diagnostic and therapeutic agents and products. The company focuses on radiopharmaceuticals and contrast media agents, which are critical in medical imaging and diagnostics. With over 30 years of experience, Lantheus demonstrates a strong track record in managing the global research and development of products across all phases, from discovery through to post-marketing life cycle management. The appointment of Jean-Claude Provost, MD, as Chief Medical Officer underscores the company's commitment to advancing its portfolio of diagnostic and therapeutic solutions. Additionally, under the leadership of Linda Lennox as Vice President, Corporate Communications and Chief of Staff, Lantheus emphasizes the importance of effective internal and external communication strategies, investor relations, and patient advocacy, aligning these efforts with the company's vision, mission, and goals. Lantheus Holdings Inc. thus plays a crucial role in enhancing patient outcomes through its specialized healthcare solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and Earnings

For Q3 2025, worldwide revenue reached $384.0 million—a 1.4% increase from Q3 2024. However, GAAP fully diluted earnings per share fell sharply to $0.41 from $1.79 year-over-year (a 77.1% decline), and adjusted fully diluted earnings per share declined to $1.27 from $1.70 (a 25.3% drop).

Operating Performance

Operating income dropped by 67.4% to $43.6 million, with adjusted operating income (non-GAAP) decreasing 27.6% to $119.6 million. These changes reflect the company’s efforts to manage challenging operating conditions during the quarter.

Capital Management and Cash Flow

Lantheus generated free cash flow of $94.7 million in Q3 2025, with net cash provided by operating activities reaching $105.3 million. In addition, the company repurchased $100 million of common stock as part of its previously announced stock repurchase plan, reinforcing its confidence in long-term value creation.

Business Developments and Strategic Initiatives

In this quarter, Lantheus advanced several strategic moves: it completed the acquisition of Life Molecular Imaging to expand its commercial portfolio, initiated a leadership transition with the upcoming retirement of the CEO, and announced key FDA updates including PDUFA target dates for its radiopharmaceutical pipeline products such as piflufolastat F 18, MK-6240, and LNTH-2501. These developments are poised to enhance both near- and long-term growth prospects.

Summarized from source with an LLMView Source

Key figures

-38.0%1Y

-7.12%3Y

328%5Y

Performance

60.5%1Y

59.0%3Y

57.2%5Y

Volatility